Text Size

Biodegradable intraocular therapies for retinal disorders: Progress to date

Kuno N., Fujii S.


  • 2010
  • Drugs and Aging
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Drug Delivery

  • Affiliations

    Research and Development Center, Santen Pharmaceutical Co. Ltd, 8916-16, Takayama-cho, Ikoma-shi, Nara 630-0101, Japan

Related Publications

Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase II/III ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y, on behalf of the ORANGE study investigators


Awareness of Myopia Associated Complications and Perspectives on Myopia Management Among Parents of Children with Myopia in France and the UK

Hafizi R., Deferne N., Paudel N., Angerer A., Hsieh H.-T.


Cutamesine (SA4503) Protects Retinal Ganglion Cells in an Ocular Hypertension Model of Glaucoma Determined Using Detection of Apoptosing Retinal Cells Technology and RBPMS Cell Marker

Sharif N.A., Takashi O., Taniguchi T., Sasaoka M., Guo L., Choi S., Luong V., Cordeiro M.F.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022